Abstract: The present invention relates to a low dose topical composition comprising triamcinolone acetonide or salt thereof in an amount of less than 250 mcg/gm, its process of preparation and its use for the treating/preventing of various types of skin diseases, preferably atopic dermatitis in infants, children, adults and elderly patients.

Abstract: The present invention relates to a novel pharmaceutical composition comprising combination of Olopatadine or salt thereof and Nepafenac or salt thereof, process for preparation thereof and use thereof for the treatment of ophthalmic disorders.

Abstract: The present invention relates to anti-aging composition comprising bioactive protein obtained by cultivation of placenta, method of preparing the composition and use as a cosmetic composition.

Abstract: A short-term storage of stem/progenitor cells in regenerative medicine without cryopreservation and cryoprotector. The protective composition of the invention improves the quality and increases the efficiency of cell therapy by keeping stem/progenitor cells free of ultra-low temperatures (liquid nitrogen) and cryoprotectants during the period of their biosafety testing and transportation to a patient’s bed.

Abstract: The present disclosure relates to the ready to use intravenous infusion of Brivaracetam or salt thereof. The ready to use intravenous infusion of Brivaracetam or salt thereof provides longer stability, which can be administered for longer period of time, with direct use without prior dilution, which saves time for dilution in case of emergency, with better ease of handling and which is efficacious; provide better patient compliance in the treatment of seizures.

Abstract: The present invention relates to Suprabioavailable oral composition of Pirfenidone or salt thereof when compared with reference product of Pirfenidone capsule [267 mg] and tablet [267 mg and 801 mg] for the treatment of idiopathic pulmonary fibrosis (IPF). The Suprabioavailable oral composition of Pirfenidone or salt thereof provides at least 5% dose reduction which minimizes adverse effects and provides more efficacy with better patient compliance in the treatment of idiopathic pulmonary fibrosis.

Abstract: A method for isolation, enrichment and co-culture of foetal polymix involving two or more components of mesenchymal stem cells derived from, but not limited to, placenta, amnion, amniotic fluid, chorion and umbilical cord and/or other products of conception under hypoxic or otherwise and/or normoxic/general conditions for treatment of a plurality of disorders ranging from congenital to degenerative to developmental to malignant disorders and diseases prior to therapeutic administration.

Abstract: The present disclosure relates to the intranasal drug delivery system or composition of Brivaracetam or salt thereof. The nasal drug delivery Brivaracetam or salt thereof preferably in the form of Nasal sprays provide more bioavailability better onset of action, lesser adverse effects; better ease of self-administration and better patient compliance in the treatment of partial-onset seizures.

Abstract: The present invention relates to antifungal cuticle oil composition comprising Efinaconazole or Tavaborole or Terbinafine or salt thereof in the treatment of onychomycosis. The topical antifungal cuticle oil according to present invention provides better penetration and application at affected site results in better efficacy and patient compliance in the treatment of onychomycosis. The said composition also combat fungus of nail, cuticle, nail bed area and skin surrounding nail, protect and nourish the nails which got brittle, inflamed, painful and white to yellow in onychomycosis.

Abstract: A method for isolation, enrichment and co-culture of foetal polymix involving two or more components of mesenchymal stem cells derived from, but not limited to, placenta, amnion, amniotic fluid, chorion and umbilical cord and/or other products of conception under hypoxic or otherwise and/or normoxic/general conditions for treatment of a plurality of disorders ranging from congenital to degenerative to developmental to malignant disorders and diseases prior to therapeutic administration.

Abstract: The present invention is directed to novel methods comprising the isolation of viable fetal progenitor cells from organs of aborted fetus. The invention comprises the use of natural proteolytic, collagenolytic and fibrinolytic activity of autologous abortive placenta tissue extract.

Abstract: The present invention relates to a method for the preparation of autologous human primary hair follicles in 3D cultures, comprising the isolation of primary fetal follicles; isolation of the patient's hair follicle cells; isolation of skin cells of the patient's scalp; extraction of growth factors from fetal follicle cells; the fibrin gel creation that contains growth factors of fetal follicles; sandwich cultivation of patient's hair follicle cells and skin of the patients scalp on or into fibrin gel that contains growth factors of fetal follicles; separation from fibrin gel the patients primary hair follicles, which can be used to treat baldness as an autologous graft.

Abstract: The present invention is directed to novel methods comprising the isolation of viable fetal progenitor cells from organs of aborted fetus. The invention comprises the use of natural proteolytic, collagenolytic and fibrinolytic activity of autologous abortive placenta tissue extract.

Abstract: A method for isolation, enrichment and co-culture of foetal polymix involving two or more components of mesenchymal stem cells derived from, but not limited to, placenta, amnion, amniotic fluid, chorion and umbilical cord and/or other products of conception under hypoxic or otherwise and/or normoxic/general conditions for treatment of a plurality of disorders ranging from congenital to degenerative to developmental to malignant disorders and diseases prior to therapeutic administration.